PRESENTATION TITLE

Managing Patients with Acute Myeloid Leukemia at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

PRESENTER(S)

Michael R. Bishop, M.D., Director, The David and Etta Jonas, Center for Cellular Therapy, Professor of Medicine, University of Chicago, Chicago, IL

VIEWING LOCATIONS
Zoom Registration Link

LEARNING OBJECTIVES

• Identify patients with acute myeloid leukemia (AML) at high-risk for relapse after allogeneic hematopoietic stem cell transplantation (HSCT).
• Review biologic and immunologic mechanisms underlying relapse of AML after allogeneic HSCT.
• Apply individualized tactics to prevent relapse of AML after allogeneic HSCT.
• Assess and select best options for treatment of relapsed AML after allogeneic HSCT.

PRESENTERS BIO

Michael R. Bishop, MD, is Professor of Medicine and the Director of the David and Etta Jonas Center for Cellular Therapy at the University of Chicago. Dr. Bishop’s research focuses on the development and conduct novel clinical trials in hematopoietic stem cell transplantation and cellular therapy. A specific area of interest includes the therapeutic use of T cells to treat relapsed malignancies.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.